PBD Vivoryon Therapeutics AG

Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million

Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.



Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million



To access the press release, please click .









EN
26/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vivoryon Therapeutics AG

 PRESS RELEASE

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will present at the following investor conferences: mwb online Health Care ConferenceDate: July 1, 2025Presentation Time: 12:00 pm CES...

 PRESS RELEASE

Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meet...

Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting Vivoryon Therapeutics N.V. Reports Outcomeof 2025 Annual General Meeting Halle (Saale) / Munich, Germany, June 24, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on diabetic kidney disease, held its Annual General Meeting (AGM) today at 1:00 p.m. (CEST). The shareholders approved all items on the agenda of the meeting, including the appointment of Dr. Julia ...

 PRESS RELEASE

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational P...

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Continued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP portfolioVaroglutamstat’s pre-clinical dataset showing synergistic effect in combination with an SGLT-2 inhibitor in different treatment regimensNovel composition of matter patent for varoglutamstat granted after accelerated review in the U.S.; patent term to provide exclusivity through 2044 with subsequent opportunity for pate...

 PRESS RELEASE

Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Ope...

Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025 Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025 Halle (Saale) / Munich, Germany, June 11, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its first quarter financial results for the period ended March 31, 2025 and pr...

 PRESS RELEASE

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and V...

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congres...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch